GlassScriptPhysician profile
Alicia R Thomas
NPI 1154787638
$7,251.30
in general payments reported to CMS, 2019-2025
40 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,170 · 2022: $616 · 2023: $1,379 · 2024: $2,829 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414 · Travel and Lodging: $973 · Education: $78.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,413.55 |
| Travel and Lodging | $973.32 |
| Education | $78.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,017.65 | 2023-2025 | Spravato |
| Abbvie INC. | $809.63 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $636.83 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lilly USA, LLC | $527.51 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Axsome Therapeutics, INC. | $438.19 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $311.29 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $279.07 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $267.69 | 2024-2025 | Lybalvi, Aristada |
| Genentech USA, INC. | $214.05 | 2021-2022 | |
| Daiichi Sankyo INC. | $151.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $139.04 | 2021-2025 | Breztri, Airsupra |
| Collegium Pharmaceutical, INC. | $121.46 | 2021 | |
| Lundbeck LLC | $120.67 | 2021-2025 | Rexulti |
| Pfizer INC. | $116.62 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.24 | 2023-2025 | Caplyta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.